a clinical-stage, cancer-selective gene therapy company, which engages in the development of product candidates designed to activate a patient's immune system against their own cancer
Industry Biotechnology
A.I.dvisor tells us that FBRX and AXON have been poorly correlated (+31% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that FBRX and AXON's prices will move in lockstep.
Ticker / NAME | Correlation To FBRX | 1D Price Change % | ||
---|---|---|---|---|
FBRX | 100% | +1.68% | ||
AXON - FBRX | 31% Poorly correlated | -1.54% | ||
ARRY - FBRX | 28% Poorly correlated | -5.02% | ||
CLNN - FBRX | 27% Poorly correlated | -1.82% | ||
CDTX - FBRX | 27% Poorly correlated | -0.70% | ||
PASG - FBRX | 27% Poorly correlated | -2.03% | ||
More |